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Abstract
Background: Because a recent cluster of false positive results on the OraQuick ADVANCEH Rapid HIV-1/2 Antibody Test
occurred in San Francisco on test kits close to their expiration date, we decided to assess the relationship between time to
expiration and rate of false positive results from tests used with oral fluid.
Methodology/Principal Findings: We analyzed results of 20,904 tests with either an initial HIV-negative result (n = 20,828)
or a preliminary positive result that was then negative on confirmatory tests (n = 76). We computed specificity for kits with
time to expiration from #1 to $6 months, with exact binomial confidence intervals, then used logistic regression to
estimate the independent association of time to expiration with false positive results, adjusting for site and technician
effects. For 1,108 kits used in the last month before expiration, specificity was 98.83% (95% exact binomial confidence
interval (CI) 98.00%–99.37%); the upper bound is below the claimed specificity of 99.60%. After adjustment using regression
standardization for the effects of site, test lot, and technician factors, adjusted specificity in the last month before expiration
was 99.18% (95% bootstrap confidence interval 98.60–99.57%).
Conclusions/Significance: We found that specificity of the OraQuick ADVANCEH with oral fluid declined significantly with
#1 month remaining to expiration, leaving little margin for error from other sources.
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Introduction
In June of 2004, the OraQuick ADVANCEH Rapid HIV-1/2
Antibody Test (OraSure Technologies, Inc., Bethehem, PA) was
approved as a CLIA-waived rapid HIV test for use with oral
mucosal transudate (oral fluid) specimens in addition to whole
blood.[1] In February of 2005, this test first became available for
point-of-care HIV antibody testing in publicly-funded HIV testing
sites in San Francisco. Because California regulations required
phlebotomy certification before performing a fingerstick or blood
draw (California Code of Regulations 1711034; California
Business and Professions Code 11240-1246.5), most community-
based testing sites in San Francisco were prevented from
performing rapid HIV tests using whole blood specimens, and
therefore the advent of an oral fluid option led to a swift,
significant increase in rapid testing in public HIV test sites
(Facente, presented at HIV Diagnostics: New Developments and
Challenges; Orlando, FL, 2005).
United States regulations currently require that all reactive
rapid HIV tests be considered ‘‘preliminary positive’’ and
confirmed in a high-complexity laboratory via Western blot
(WB) or indirect immunofluoresence assay (IFA).[2] In cases where
the WB or IFA is negative or indeterminate, the results are
considered ‘‘discordant’’ and follow up testing is indicated. This
follow up testing is needed to determine whether the original
reactive result was a false positive or if the patient has HIV
infection but is in early seroconversion, causing the tests used for
confirmation – some with lower sensitivity – to fail to detect
antibodies.[3] From 2003 through early 2006 in San Francisco, all
patients with discordant results were asked to submit blood
specimens after one month for follow up testing according to the
above protocol. This was done regularly with all patients who were
successfully contacted one month after the initial result disclosure.
In February of 2006, with the agreement of the California
Department of Public Health, Office of AIDS and Centers for
Disease Control and Prevention, San Francisco began using a new
algorithm that included the use of Nucleic Acid Amplification
Testing (NAAT) to resolve most discordant tests from the first visit
(Dowling and Facente, presented at XVI International AIDS
Conference; Toronto, Canada, 2006). From this point forward,
follow up testing was not regularly done if an oral fluid rapid HIV
test was reactive but blood drawn that same day yielded non-
reactive results for another OraQuick rapid test, an EIA, an IFA
and/or WB, and NAAT.
According to the manufacturer, the OraQuick ADVANCEH has
a specificity of 99.8% (95% Confidence Interval (CI) 99.60%–
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99.89%) when used with oral fluid.[4] However, clusters of excess
false positive results have been well documented[5–8], including in
San Francisco. To date, these false positive clusters have remained
unexplained, with issues such as test kit lot defect, storage or
testing area temperature, and operator error being generally ruled
out as causes.[9]
In April – July 2008, we noticed a cluster of false positive test
results in San Francisco which occurred with kits close to their
expiration date, and decided to further investigate the association
between kit expiration and false positive results. We hypothesized
that there would be a greater probability of false positive results as
the kit approached its expiration date.
Materials and Methods
Test Kits
The OraQuick ADVANCEH test kits used in this analysis were
provided at no cost to the San Francisco Department of Public
Health from the California Department of Public Health, Office of
AIDS, then distributed to HIV testing sites located throughout the
city of San Francisco. Test kits were shipped directly from the
manufacturer to the San Francisco Department of Public Health
upon ordering, and external controls were run on all new boxes of
test kits upon opening before use with patients. The shelf life of the
test kits used in this analysis was six months, with the exception of
a small number of kits that were an early version of the OraQuick
ADVANCEH that was FDA-approved with a longer shelf life.
Actual expiration dates for these kits were changed in our analysis
to reflect a consistent 6-month shelf life. Results for 56 kits
(including 1 false positive result) used shortly after the adjusted
expiration date were omitted from the analysis.
A new version of the OraQuick ADVANCEH, which became
available to consumers in February 2009, was FDA-approved with
a 12-month shelf life following a change in manufacturing and
quality control processes to increase consistency of the prod-
uct[10]. No kits of this enhanced version were used in this analysis.
Test Records
All HIV antibody tests run in publicly-funded test sites in
California are recorded on a standardized laboratory requisition
slip. In San Francisco, these slips are submitted on a monthly basis
to the San Francisco Department of Public Health for review and
data entry. Test technicians at each testing site are trained and
certified to run the OraQuick ADVANCEH[11] and are specifically
instructed to systematically record lot number, expiration date,
specimen date, specimen type, and test result for all rapid HIV
tests they conduct.[12] Each of these details are individually
entered into a database, along with final confirmation results for all
positive tests. Extra details and technician notes are maintained for
all discordant test results. For each test, we computed time to
expiration as the interval from the date the kit was used to the last
day of the month and year of the expiration date printed on the
test pouch, as recorded in the database.
Statistics
Specificity was computed for kits for time to expiration by
month, from #1 to $6 months until expiration, with exact
binomial confidence intervals. Logistic regression was then used to
estimate the association of time to expiration with a false positive
result. We tested for trend in the false positive rate across months
using an orthogonal contrast; this procedure can be viewed as a
linear regression of the month-by-month log odds ratios on the
number of months to expiration. [13] In addition, we adjusted for
the effects of test site, test lot, and technician. Because there were
only 76 false positive results, but numerous lots (n = 129),
technicians (n = 210), and sites (n = 22), it was not possible to
adjust for these factors by the conventional means of including
indicator variables for each lot, technician, and site in the model.
To deal with this problem, we classified sites, lots, and technicians
according to whether their observed false positive rates were
#0.5%, .0.5% and ,1.0%, or $1.0%, representing acceptable,
borderline, and clearly unacceptable rates, and then controlled for
these classifications. Goodness of fit was assessed using the
Hosmer-Lemeshow statistic.
We calculated adjusted specificity by months to expiration using
regression standardization[14]. Specifically, the fitted probability
of a true negative result was computed for each of the 20,904
observations for all six possible values of months to expiration,
holding all other covariates at their observed values. Then
specificity for each month was estimated by averaging – over the
identical covariate distributions – the 20,904 fitted values for that
month. In a final step, bias-corrected bootstrap percentile
confidence intervals were calculated for these regression-standard-
ized specificities.
We considered associations with p-values,0.05 to be statisti-
cally significant. All analyses were done using Stata Version 11
(Stata Corp., College Station, TX).
Results
Results were analyzed for 20,904 tests performed between
January 2005 and December 2007, with either an initial HIV-
negative result (n = 20,828), or a preliminary positive result that
proved to be false positive after confirmation by IFA or WB
(n= 76). Test results by months remaining until expiration are
shown in Table 1. Of 1,108 test kits used with #1 month until
expiration, 13 (1.17%) were false positive, corresponding to a
sample specificity of 98.83% (exact binomial 95% CI 98.00%–
99.37%).
Table 1. Test specificity by time to expiration.
Time to Expiration (months) Total Tests (N) False Positive Tests (N, %) Specificity (%) 95% Exact Binomial Confidence Interval
#1 1108 13 (1.17%) 98.83 98.00–99.37
2 2206 14 (0.63%) 99.37 98.94–99.65
3 4968 24 (0.48%) 99.52 99.28–99.69
4 6770 16 (0.24%) 99.76 99.62–99.86
5 4601 8 (0.17%) 99.83 99.66–99.92
$6 1251 1 (0.08%) 99.92 99.56–99.99+
doi:10.1371/journal.pone.0008217.t001
OraQuick False Positives
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In the unadjusted logistic regression, the odds of a false positive
result were higher for the 1,108 test kits used #1 month before
expiration, compared to 1,251 kits with $6 months until
expiration (Odds Ratio (OR) 14.8, 95% CI 1.94–113.6,
p = 0.009). False positive rates were also elevated for 2,206 kits
with two (OR 7.98, 95% CI 1.05–60.8, p= 0.045) and 4,968 kits
with three (OR 6.07, 95% CI 0.82–44.9, p = 0.08) months until
expiration. Although the rates for months two and three were
similar (OR 1.32, 95% CI 0.68–2.55, p = 0.42), the linear trend
across the six months was highly statistically significant
(p = 0.0008). Results were similar in the adjusted model, shown
in Table 2. The contrast between months one and six (OR 11.5,
95% CI 1.49–89.4, p = 0.019) and the trend across months
(p = 0.0057) both remained strong. Six of 129 lots (4.7%), eight of
210 technicians (3.8%) and two of 22 sites (9.1%) had false positive
rates of 0.5% to 1.0%, while three lots (2.3%), 13 technicians
(6.2%), and two sites (9.1%) had rates greater than 1.0%. These
categorizations of lot and technician but not site were important
independent predictors in this model, which fit well (Hosmer-
Lemeshow p-value = 0.77). Results were similar using other
specifications of the adjusted model, and in sensitivity analyses,
we found no evidence for effects of calendar month (p = 0.51 for
heterogeneity) or calendar year (p = 0.22), after adjusting for lot,
technician, and site. In the last month before expiration, adjusted
specificity estimated using regression standardization was 99.18%
(95% bootstrap confidence interval 98.60–99.57%) (Figure 1).
Discussion
We found that the rate of false positive results was significantly
higher for oral rapid HIV test kits used with #1 month remaining
until expiration as compared to kits used with $6 months
remaining until expiration, after adjustment for the effects of
technician and site. Before adjustment, both the point estimate
(98.83%) and upper bound of an exact 95% confidence interval
(99.37%) for the specificity of tests used with #1 month until
expiration were below the lower bound for specificity claimed by
the manufacturer (99.60%). After regression standardization, the
point estimate (99.18%) and upper 95% bootstrap confidence limit
(99.57%) both remained below the manufacturer’s lower bound.
Although residual confounding cannot be ruled out, this suggests
that site, lot, and technician effects do not explain our findings,
and reflect the rigorous quality assurance system that San
Francisco has implemented since the beginning of rapid HIV
testing.[15] However, no matter how rigorous a quality assurance
system is, some errors will inevitably occur, especially in a non-
clinical setting. For example, a well-intentioned technician may
swipe the patient’s gums with the test kit paddle twice rather than
once in an effort to ensure adequate sample collection, or a site’s
lighting may be improvised in a mobile van, making it more
difficult for some technicians to clearly see an extremely faint test
line. Ideally, a CLIA-waived test kit will be sufficiently robust to
mitigate these factors. It is clear from our results that as these
OraQuick ADVANCEH test kits age, the overall testing specificity
decreases when used with oral fluid, and that tests used within one
month of expiration leave little margin for errors from these other
sources.
We also found an independent association of test technician on
specificity in our adjusted analysis. However, several of the
technicians with high false positivity rates had performed very few
tests overall, making it difficult to reliably identify those with
higher expected long-term rates. Furthermore, test technicians in
publicly-funded test sites in the State of California attend aK day
training, pass a multi-stage proficiency test, and must successfully
complete competency assessment testing at least once per year
following initial certification. Despite this, they do not have
extensive laboratory training, and it is unrealistic to expect that
they will always conduct the test perfectly and with no variation.
Again, any CLIA-waived, point-of-care test should be sufficiently
robust to maintain accuracy given inevitable variations in
technician performance.
Since the first cluster of false positive results in San Francisco in
late 2005, significant attention has been paid here to a variety of
other factors that could possibly be the cause of such a cluster,
particularly factors by site and technician. Test storage practices
by site, temperature regulation and monitoring at each site,
conditions during transport of test kits (i.e. with mobile testing),
eyesight of test readers, lighting conditions at each site, and the
Table 2. Multivariable logistic model for false positive test results.
Predictor Adjusted Odds-Ratio 95% Confidence Interval P-value
Time to Expiration (months) #1 11.5 1.49–89.4 0.019
2 5.54 0.71–42.9 0.10
3 7.05 0.95–52.6 0.06
4 3.70 0.49–28.2 0.21
5 2.72 0.34–21.9 0.35
$6 ref - -
Site False Positive Rate (%) .1.0 0.74 0.36–1.54 0.42
0.5–1.0 1.86 0.98–3.54 0.06
,0.5 ref - -
Technician False Positive Rate (%) .1.0 21.5 10.6–43.7 ,0.001
0.5–1.0 7.79 3.89–15.6 ,0.001
,0.5 ref - -
Lot False Positive Rate (%) .1.0 4.57 2.27–9.21 ,0.001
0.5–1.0 4.77 2.59–8.78 ,0.001
,0.5 ref - -
doi:10.1371/journal.pone.0008217.t002
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opportunity for disruption of test kits during processing were all
factors that were reviewed at length at all sites in San Francisco.
No patterns related to false positive results were detected and no
dramatic variations between sites were observed, leading us to
believe these factors were not significant to this analysis.
Previous investigations have not successfully determined a cause
for the intermittent clusters of false positive results seen around the
country since the introduction of the OraQuick ADVANCEH when
used with oral fluid.[5–9] Our results, however, offer one potential
explanation. They also fit with patterns of test kit use relative to the
expiration date, as a result of shipping schedules and quantity of
test kits in stock for a particular jurisdiction.[16]
Rapid HIV testing is a critical public health intervention. Not
only does it improve access to serological testing for millions of
Americans at risk for HIV, but it does so while providing same-day
screening results to all patients, with only people testing
preliminary positive needing to wait the 7- to 14-days for IFA or
WB results. In the United States, the Centers for Disease Control
and Prevention as well as numerous state and city governments
have spent millions of dollars purchasing the OraQuick ADVAN-
CEH as a cornerstone of this intervention.[17–19] This test, used
with oral fluid, is currently the most widely used point-of-care
rapid HIV test in the country (Wesolowski, Burstein, Zhu, and
Ethridge. Presented at HIV Diagnostics: New Developments and
Challenges; Orlando, FL, 2005). For these reasons, it is imperative
to resolve issues of clustering false positive results with oral fluid in
order to continue its use to assist in diagnosing new HIV
infections.
Anecdotal experiences from various jurisdictions indicate a
marked reduction in false positive results using the most recent
version of the OraQuick ADVANCEH, released in February 2009.
However, additional analyses should be conducted with data sets
in jurisdictions using these new tests, to confirm that test remains
robust throughout the current 12-month shelf life claim when the
test is run in typical field conditions, and that policy changes and
procedural adaptations – such as discontinuing use when kits are
within a month of expiration – are not necessary in order to ensure
adequate specificity. Finally, CDC and Association of Public
Health Laboratories’ approval of a rapid multi-test algorithm for
point-of-care resolution of false positive results in the United States
could also address these issues and eliminate the need, in most
cases, for additional testing and prolonged uncertainty regarding
an individual’s HIV status.
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